Non-Invasive Screening for Fetal Aneuploidy

UnknownOBSERVATIONAL
Enrollment

340

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Down SyndromeEdwards Syndrome
Interventions
OTHER

Maternal Blood Draw

Maternal Blood Draw

Trial Locations (10)

37403

Regional Obstetrical Consultants, Chattanooga

76104

Obstetrix Medical Group of Texas, Fort Worth

77380

Obstetrix Medical Group of Houston, The Woodlands

80113

OBX Med. Group. of Colorado - Perinatal Resource Ctr @ Swedish Med Ctr., Englewood

80124

OBX Med. Group. of Colorado - Skyridge, Lone Tree

80205

OBX Med. Group. of Colorado - Pres/St Luke's Clinic, Denver

80220

OBX Med. Group. of Colorado - Antepartum Testing Unit @ Rose Medical Center, Denver

90806

Long Beach Memorial Medical Ctr - 2nd Floor Perinatal, Long Beach

92708

Obstetrix Medical Group of California, Campbell

98122

Obstetrix, Medical Group of Washington, Inc. - Swedish Medical Center, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Obstetrix Medical Group

INDUSTRY

lead

Progenity, Inc.

INDUSTRY

NCT02317965 - Non-Invasive Screening for Fetal Aneuploidy | Biotech Hunter | Biotech Hunter